Gert Fricker | Drug Delivery | Excellence in Research Award

Published on by ScienceFather

Prof. Dr. Gert Fricker | Drug Delivery | Excellence in Research Award

Diretor at University of Heidelberg, Germany

Prof. Dr. Gert Fricker is Director of the Institute of Pharmacy and Molecular Biotechnology at Heidelberg University, Germany, where he also leads the Department of Pharmaceutical Technology and Biopharmacy. He earned his Ph.D. from the University of Freiburg with a focus on transcellular bile acid transport, followed by a habilitation in Experimental Medicine. His career spans academia and industry, including key roles at Sandoz Pharma AG and as CEO of the Steinbeis-Technology Transfer Center for Biopharmacy and Analytics. A pioneer in drug delivery systems, Prof. Fricker co-founded Heidelberg Delivery Technologies GmbH to advance oral peptide and protein therapeutics. His research centers on drug transport across biological barriers, ABC transporters, and drug formulation strategies. He has authored over 250 peer-reviewed publications, contributed to more than 60 books, and holds 14 patent applications. Among his accolades are the Phoenix Pharmacy Science Awards, the Dietrich-Schmähl Award, and the APV Research Award for outstanding pharmaceutical research.

Professional Profile:

SCOPUS

ORCID

🏆 Summary of Suitability: Prof. Dr. Gert Fricker Nomination for the Excellence in Research Award

Prof. Dr. Gert Fricker is an internationally distinguished pharmaceutical scientist whose decades-long contributions to drug delivery, biopharmaceutics, and membrane transport mechanisms have significantly advanced the field of pharmaceutical sciences. His profound academic rigor, interdisciplinary leadership, and translational impact make him an exceptional candidate for the Excellence in Research Award.

🎓 Education

  • 🧪 University of Freiburg, Germany (1975–1986)
    ➤ Studied Chemistry and Medicine

  • 📜 Ph.D. in Experimental Medicine (1986)
    ➤ Thesis: Transcellular Transport of Bile Acids in the Liver

  • 📘 Habilitation (1993)
    ➤ Field: Experimental Medicine
    ➤ Thesis: Pathomechanisms of Obstructive Cholestasis and Estradiol-Induced Intrahepatic Cholestasis

💼 Professional Experience

  • 🧬 Postdoctoral Fellow, Clinical Pharmacology, University Hospital Zürich, Switzerland (1986–1988)

  • 🧪 Research Scientist, Drug Delivery Systems, Sandoz Pharma AG, Basel, Switzerland (1988–1995)

  • 👨‍🏫 Professor, Institut für Pharmazeutische Technologie und Biopharmazie, University of Heidelberg (1995–2002)

  • 🎓 Director, Institut für Pharmazeutische Technologie und Biopharmazie, University of Heidelberg (1997–2002)

  • 🧫 Director, Institute of Pharmacy and Molecular Biotechnology, Faculty of Biosciences, University of Heidelberg (since 2002)

  • 🧪 CEO, Steinbeis Technology Transfer Center for Biopharmacy and Analytics, Heidelberg (since 1998)

  • 💊 Co-founder & Partner, Heidelberg Delivery Technologies GmbH (HeiDelTec) (since 2017)

🔬 Research Interests

  • 🧠 Drug transport across the Blood-Brain Barrier (BBB)

  • 🏥 Hepatic and membrane transport mechanisms

  • 💊 ABC transporters, drug absorption enhancement

  • 🎯 Targeted drug delivery and pharmaceutical formulations

🏆 Awards & Honors

  • 🧪 Phoenix Pharmacy Science Awards (2003, 2008)
    ➤ For outstanding scientific contributions in pharmaceutical technology and pharmacology

  • 🎗️ Dietrich-Schmähl Award (2003)
    ➤ From the Central European Society for Anticancer Drug Research

  • 🧫 APV Research Award (1998)
    ➤ Association of Pharmaceutical Technology for excellence in pharmacy

📚Publication Top Notes

Truncated mini LRP1 transports cargo from luminal to basolateral side across the blood brain barrier

Cited : 2

Increased Expression of Transferrin Receptor 1 in the Brain Cortex of 5xFAD Mouse Model of Alzheimer’s Disease Is Associated with Activation of HIF-1 Signaling Pathway

Cited : 6

Low-Density Lipoprotein Receptor-Related Protein 1 as a Potential Therapeutic Target in Alzheimer’s Disease

Cited : 9

Assoc. Prof. Dr. Kyeong Soo Kim | Pharmaceutics Awards | Excellence in Research

Published on by ScienceFather

Assoc. Prof. Dr. Kyeong Soo Kim | Pharmaceutics Awards | Excellence in Research

Assoc. Prof. Dr. Kyeong Soo Kim  , Gyongsang National University/Dept. of Pharmaceutical Engineering , South Korea

Kyeong Soo Kim is an accomplished researcher and academic based in the Republic of Korea. He currently serves as an Associate Professor in the Department of Pharmaceutical Engineering at Gyeongsang National University. Dr. Kim earned his Ph.D. in Pharmacy from Hanyang University, where he specialized in the development of novel controlled release formulations for fenofibric acid. His research interests span nanotechnology applications for poorly water-soluble drugs, improved pharmaceutical technologies for controlled release dosage forms, inhaled drug delivery systems, and dermal drug delivery systems. Prior to his current position, he held roles as a Postdoctoral Research Associate at the University of Mississippi and as a Principal Scientist at Hanmi Pharm. Co., Ltd., where he gained extensive experience in formulation and process development. Dr. Kim’s expertise includes designing oral and parenteral dosage forms, conducting preformulation studies, and utilizing advanced techniques such as solid dispersion, spray drying, and lipid-based formulations to enhance drug delivery efficacy. He is actively involved in research and has contributed significantly to the field through his publications and professional engagements.

Professional Profile:

Scopus

🎓Education:

Kyeong Soo Kim is a distinguished academic and researcher in the field of pharmacy, currently holding the position of Associate Professor at Gyeongsang National University in the Republic of Korea. He completed his Ph.D. in Pharmacy at Hanyang University from March 2011 to August 2015, under the guidance of Professor Han-Gon Choi, Ph.D. His doctoral research focused on the development of innovative controlled release formulations for fenofibric acid. Prior to his doctoral studies, he earned a Master of Science in Pharmacy at Chungbuk National University from March 2002 to August 2004, where his research investigated the depigmenting effects and mechanisms of piperlonguminine derived from Piper longum. Kyeong Soo Kim began his academic journey with a Bachelor of Science in Pharmacy, also from Chungbuk National University, completed from March 1998 to February 2002. His educational background underscores his expertise in pharmaceutical sciences, particularly in drug delivery systems and formulation development.

 🏢Work Experience:

Kyeong Soo Kim is currently an Associate Professor in the Department of Pharmaceutical Engineering at Gyeongsang National University in the Republic of Korea, a position he has held since September 2017. Prior to joining Gyeongsang National University, Dr. Kim served as a Postdoctoral Research Associate at the Department of Pharmaceutics and Drug Delivery, School of Pharmacy, The University of Mississippi, USA, from September 2016 to August 2017. Before his time in the United States, he worked as a Postdoctoral Research Fellow at the Laboratory of Industrial & Physical Pharmacy at Hanyang University, Republic of Korea, from September 2015 to August 2016. Dr. Kim’s extensive professional experience also includes a significant tenure as a Principal Scientist and Team Manager at the Pharmaceutical R&D Center of Hanmi Pharm. Co., Ltd., Republic of Korea, where he contributed from August 2004 to November 2014. His career path highlights his expertise in pharmaceutical engineering, drug delivery systems, and research leadership in both academic and industrial settings.

Publication Top Notes:

  • “Improved bioavailability and high photostability of methotrexate by spray-dried surface-attached solid dispersion with an aqueous medium” by Giri, B.R., Kim, J.S., Park, J.H., … Choi, H.G., Kim, D.W.
    • Journal: Pharmaceutics, 2021, 13(1), pp. 1–14, 111
    • Citations: 36
  • “Nitration of protein phosphatase 2A increases via Epac1/PLCε/CaMKII/HDAC5/iNOS cascade in human endometrial stromal cell decidualization” by Lee, S.Y., Lee, Y.Y., Choi, J.-S., … Park, S.-Y., Han, J.-S.
    • Journal: FASEB Journal, 2020, 34(11), pp. 14407–14423
    • Citations: 2
  • “Development of Novel d-Cycloserine Tablet with Improvement of Drug Stability and Dissolution-Equivalence to the d-Cycloserine-Loaded Commercial Hard Capsule” by Kim, J.S., Choi, Y.J., Woo, M.R., … Jin, S.G., Choi, H.-G.
    • Journal: Bulletin of the Korean Chemical Society, 2020, 41(6), pp. 603–608
    • Citations: 3
  • “Enhanced Chemical Stability of D-Cycloserine via Tablet Form Containing Magnesium Oxide as an Alkali Stabilizer” by Kim, J.S., Lee, S.M., Kim, D.S., … Jin, S.G., Choi, H.-G.
    • Journal: Bulletin of the Korean Chemical Society, 2020, 41(1), pp. 10–14
    • Citations: 1
  • “Self-microemulsifying drug delivery system (SMEDDS) for improved oral delivery and photostability of methotrexate” by Kim, D.S., Cho, J.H., Park, J.H., … Choi, H.-G., Kim, D.W.
    • Journal: International Journal of Nanomedicine, 2019, 14, pp. 4949–4960
    • Citations: 61